The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

trimeris.com

Founded Year

1993

Stage

Acq - P2P | Acquired

Total Raised

$30.35M

About Trimeris

Trimeris is a development stage, biopharmaceutical company engaged in the discovery and development of novel therapeutic agents that block viral infection by inhibiting viral fusion with host cells. Trimeris' lead product candidate, T-20, is now entering Phase III clinical trials. Trimeris' second fusion inhibitor product candidate, T-1249, which also inhibits HIV fusion, has received fast-track designation from the FDA and is undergoing Phase I/II clinical testing.

Trimeris Headquarter Location

2530 Meridian Parkway 2nd Floor

Durham, North Carolina, 27713,

United States

919-806-4682

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Trimeris Patents

Trimeris has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/20/2008

10/11/2011

Clusters of differentiation, G protein coupled receptors, HIV/AIDS, Peptides, Protein domains

Grant

Application Date

10/20/2008

Grant Date

10/11/2011

Title

Related Topics

Clusters of differentiation, G protein coupled receptors, HIV/AIDS, Peptides, Protein domains

Status

Grant

Latest Trimeris News

Synageva BioPharma Announces Completion of Merger with Trimeris

May 6, 2015

- Creates Clinical Stage Public Company Focused on Development of Rare Disease Therapeutics - LEXINGTON, Mass., Nov 03, 2011 (BUSINESS WIRE) -- Synageva BioPharma Corp. ,("Synageva") (NASDAQ:GEVA) a clinical stage biopharmaceutical company developing therapeutic products for rare disorders has announced that following the special meeting of shareholders on November 2, 2011, the Synageva and Trimeris, Inc. merger has closed. The combined company, which now trades on the NASDAQ Global Market under the symbol "GEVA", is called Synageva BioPharma Corp. and operates under the leadership of Sanj K. Patel, President and Chief Executive Officer. The company's board of directors consists of representatives from both the former Synageva and Trimeris boards. "The closing of this merger marks a significant milestone for Synageva. The company has made the important transition from a private to a public company using an approach which provides an immediate increase in financial resources as well as an ongoing royalty stream and a NASDAQ listing," said Sanj K. Patel, President and Chief Executive Officer of Synageva. These funds will be used to advance our LAL Deficiency program towards commercialization and progress our other promising drug candidates. We remain focused on developing treatments that make a meaningful impact on the lives of patients suffering from rare diseases. " Prior to the merger, Trimeris effected a 1-for-5 reverse stock split of its outstanding common stock. After giving effect to the reverse stock split, each former share of Synageva (on an as converted basis) was converted into the right to receive approximately 0.413 shares of the combined company's common stock. All options and warrants of Synageva that were outstanding prior to the merger were assumed by the combined company in the merger. The combined company has approximately 17.5 million shares outstanding and, on a fully diluted basis, 19.4 million shares. About Synageva's Lead Program SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD). The product is a recombinant form of the human LAL enzyme. SBC-102, currently being evaluated in global Phase I/II clinical trials, has been granted orphan designations by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency, and fast track designation by the FDA. About LAL Deficiency Lysosomal Acid Lipase Deficiency is a rare, autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease or almost complete absence of the lysosomal enzyme, lysosomal acid lipase (LAL). Late onset LAL Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In these patients, the buildup of fatty material in the liver, spleen and blood vessel walls leads to complications resulting in significant morbidity and mortality. Early onset LAL Deficiency, sometimes called Wolman Disease, affects infants in the first year of life and is characterized by growth failure, malabsorption, steatorrhea, profound weight loss, and hepatomegaly and is rapidly fatal, usually within the first year of life. About Synageva BioPharma Corp. Synageva is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Synageva has several protein therapeutics in its pipeline , including two enzyme replacement therapies for lysosomal storage disorders and two additional programs for other life-threatening genetic conditions for which there are currently no approved treatments. The company has assembled a team with a proven record of bringing orphan therapies to patients. Further information regarding Synageva BioPharma Corp. is available at http://www.synageva.com . Forward-Looking Statements Statements in this press release regarding the combined company's cash; expectations and prospects of the development of the combined company's product candidates; the combined company's management and board of directors; and any other statements about Trimeris' or Synageva's management teams' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "plans," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the risk that Synageva 's product candidates do not demonstrate safety and/or efficacy in clinical trials; the risks associated with reliance on collaborative partners; risks involved with development and commercialization of product candidates; risks relating to the combined company's ability to obtain the substantial additional funding required to conduct its development and commercialization activities; the potential inability of the combined company to obtain, maintain and enforce patent and other intellectual property protection for its products, discoveries and drug candidates; and other risks and uncertainties more fully described in Trimeris' Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, each as filed with the SEC, as well as the other filings that Trimeris makes with the SEC. Investors and stockholders are also urged to read the risk factors set forth in the joint proxy statement/prospectus filed with the SEC on October 13, 2011 carefully. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release. SOURCE: Synageva BioPharma Corp.

  • When was Trimeris founded?

    Trimeris was founded in 1993.

  • Where is Trimeris's headquarters?

    Trimeris's headquarters is located at 2530 Meridian Parkway, Durham.

  • What is Trimeris's latest funding round?

    Trimeris's latest funding round is Acq - P2P.

  • How much did Trimeris raise?

    Trimeris raised a total of $30.35M.

  • Who are the investors of Trimeris?

    Investors of Trimeris include Synageva BioPharma, Baker Brothers Investments, Lawrence and Company, Putnam Investments, Narragansett Asset Management and 29 more.

  • Who are Trimeris's competitors?

    Competitors of Trimeris include Oligomerix, Innate Pharma, Orexigen Therapeutics, ARIAD Pharmaceuticals, Alios BioPharma and 12 more.

You May Also Like

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

A
Action Pharma

a biopharmaceutical company founded in 2000 and located in Denmark The company's main strategy is to bring drug candidates rapidly from pre-clinical development into clinical trials for subsequent partnering.The goal is to bring one drug candidate into clinical development per year and currently two lead candidates are in clinical development. The company plan to seek partners for late clinical development and commercialisation of the company's drug candidates after successful development in phase I or II by partnering with major biotech and pharmaceutical companies.

A
Ascenta Therapeutics

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).On June 7, 2010, Ascenta Therapeutics was acquired by Sanofi at a valuation of $398M.

C
CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.